The FDA issued a dreaded Complete Response Letter rejecting the therapy intended for paediatric steroid-refractory acute graft versus host disease. In the letter the FDA asked for at least one ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence ...